Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324581 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT03324581 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 239 participants.
The verdict
NCT03324581, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
Interventions
- DRUG Placebo
- DRUG Atomoxetine
- DRUG OPC-64005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2017-11-09 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03324581
The ClinicalTrials.gov registry entry for NCT03324581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03324581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03324581 about?
NCT03324581 is a clinical study titled "The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder". A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
What is the current status of trial NCT03324581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2017-11-09. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT03324581?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG), OPC-64005 (DRUG).
Who is sponsoring clinical trial NCT03324581?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.